var data={"title":"Azathioprine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Azathioprine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5689?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">see &quot;Azathioprine: Drug information&quot;</a> and <a href=\"topic.htm?path=azathioprine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Azathioprine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708623\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Chronic immunosuppression with azathioprine, a purine antimetabolite, increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Health care providers using this drug should be very familiar with this risk, as well as with the mutagenic potential to both men and women, and with possible hematologic toxicities. Inform patients of the risk of malignancy with azathioprine.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138216\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Azasan;</li>\n      <li>Imuran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138217\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Azathioprine;</li>\n      <li>Imuran;</li>\n      <li>Mylan-Azathioprine;</li>\n      <li>Teva-Azathioprine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045373\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045366\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">see &quot;Azathioprine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients with intermediate TPMT activity may be at risk for increased myelosuppression; those with low or absent TPMT activity receiving conventional azathioprine doses are at risk for developing severe, life-threatening myelotoxicity. Dosage reductions are recommended for patients with reduced TPMT activity. <b>Note:</b> IV dose is equivalent to oral dose (dosing should be transitioned from IV to oral as soon as tolerated).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis, autoimmune:</b> Limited data available: Children and Adolescents: Oral: Initial: 0.5 mg/kg/dose once daily; titrate as needed up to 2 mg/kg/dose once daily; for long-term therapy, a low-dose of 1 to 1.5 mg/kg/day may be effective in some patients (Della Corte, 2012; Vitfell-Pedersen, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Inflammatory bowel disease:</b> Limited data available: Infants, Children, and Adolescents: Oral: 2 to 2.5 mg/kg/dose once daily; titrate to effect; usual reported range: 1 to 3 mg/kg/dose once daily; reported maximum daily dose: 4 mg/kg/day or 200 mg/day; may takes several weeks of therapy to be fully effective (Fuentes, 2003; Punati, 2011; Riello, 2011; Sandhu, 2010). Some data suggest that pediatric patients &le;6 years may require higher doses to achieve remission; a median dose of 3.51 mg/kg/day (maximum daily dose: 5 mg/kg/day) was reported to induce remission in 62% of patients &le;6 years of age vs 17% of those receiving lower doses (ie, &lt;2 to 3 mg/kg/day study group; median dose: 2.46 mg/kg/day) (Grossman, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Immune thrombocytopenia (ITP), chronic refractory:</b> Limited data available: Children &ge;2 years and Adolescents: Oral: Maintenance: 2 to 2.5 mg/kg/day, rounded to the nearest 50 mg (Boruchov, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile-idiopathic arthritis (rheumatoid arthritis):</b> Limited data available: Children and Adolescents: Oral: 2 to 2.5 mg/kg/dose once daily; data limited to single double-blind, placebo-controlled trial of pediatric patients (n=17 treatment group); efficacy results were not statistically significant (response rate: Treatment: 41% vs placebo: 27%); data suggested a minimum trial of 12 weeks to fully assess therapeutic response (AHRQ, 2011; Hashkes, 2005; Kvien, 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lupus nephritis, mild:</b> Limited data available: Children and Adolescents: Oral: 2 to 2.5 mg/kg/dose once daily (Bertsias, 2012; Marks, 2010); <b>Note: </b> Some data suggest less effective in non-Caucasian pediatric patients; some centers recommend use for primary induction in Caucasian patients with less severe disease (Adams, 2006; Marks, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenia gravis, juvenile:</b> Limited data available: Children and Adolescents: Oral: 1 to 3 mg/kg/dose once daily (Ashraf, 2006; Lindner, 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplantation, solid organ:</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 3 to 5 mg/kg/dose once daily, beginning at the time of transplant; maintenance: 1 to 3 mg/kg/dose once daily (Denfield, 2010; Ford, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Uveitis, JIA-associated:</b> Limited data available: Children and Adolescents: Oral: Initial mean dose: 2.4 mg/kg/dose once daily; reported range: 1.4 to 3.2 mg/kg/dose once daily; in a retrospective review of 41 children, a mean maintenance 2.1 mg/kg/dose (range: 1 to 2.8 mg/kg/dose) once daily was reported as monotherapy and/or in combination with other immunosuppressive agents; infectious etiology was excluded; the authors recommend doses of &lt;3 mg/kg/day (Goebel, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal transplantation (treatment usually started the day of transplant; however, has been initiated [rarely] 1 to 3 days prior to transplant):</b> Oral: Initial: 3 to 5 mg/kg/day usually given as a single daily dose, then maintenance 1 to 3 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 1 mg/kg/day (50 to 100 mg) given once daily or divided twice daily for 6 to 8 weeks; may increase by 0.5 mg/kg every 4 weeks until response or up to a maximum daily dose of 2.5 mg/kg/<b>day</b>; an adequate trial should be a minimum of 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Reduce dose by 0.5 mg/kg (~25 mg daily) every 4 weeks until lowest effective dose is reached; optimum duration of therapy not specified; may be discontinued abruptly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant use with allopurinol:</b> In pediatric patients, limited data is available; in adult patients, the following has been suggested: Reduce azathioprine dose to one-third or one-fourth the usual dose when used concurrently with allopurinol. Patients with low or absent TPMT activity may require further dose reductions or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for toxicity:</b> In pediatric patients, limited data is available, in adult patients the following has been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rapid WBC count decrease, persistently low WBC count, or serious infection: Reduce dose or temporarily withhold treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe toxicity in renal transplantation: May require discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease): Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents (Aronoff, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73m<sup>2</sup>: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 50 mL/minute/1.73m<sup>2</sup>: Administer 75% of dose once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73m<sup>2</sup>: Administer 50% of dose once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis (dialyzable; ~45% removed in 8 hours): Administer 50% of normal dose once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CAPD: Administer 50% of normal dose once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CRRT: Administer 75% of normal dose once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: There are no specific dosage adjustments provided in manufacturer's labeling; however, oliguric patients, particularly those with tubular necrosis in the immediate post-transplant period (cadaveric transplant) may have delayed clearance and typically receive lower doses. The following adjustments have been recommended (Aronoff, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute: Administer 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Administer 50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis (dialyzable; ~45% removed in 8 hours): Administer 50% of normal dose; supplement: 0.25 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CRRT: Administer 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138195\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azasan: 75 mg, 100 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imuran: 50 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138180\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045376\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with food or may administer in divided doses to decrease GI upset.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130888\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) when compounding. Double gloving and a gown are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138211\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Reconstituted solution should be used within 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light and moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045375\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct with other agents in prevention of kidney transplant rejection (FDA approved in adults); management of active rheumatoid arthritis (FDA approved in adults); has also been used as an immunosuppressant in a variety of autoimmune diseases such as SLE, juvenile idiopathic arthritis (JIA), JIA-associated uveitis, myasthenia gravis, and autoimmune hepatitis, and as a steroid-sparing agent for inflammatory bowel disease  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138271\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AzaTHIOprine may be confused with azaCITIDine, azidothymidine, azithromycin, Azulfidine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imuran may be confused with Elmiron, Enduron, Imdur, Inderal, Tenormin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Azathioprine is metabolized to mercaptopurine; concurrent use of these commercially-available products has resulted in profound myelosuppression.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138268\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Malaise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea and vomiting (rheumatoid arthritis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic and oncologic: Leukopenia (more common in renal transplant), neoplasia (renal transplant), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity, increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Increased susceptibility to infection (more common in renal transplant; includes bacterial, fungal, protozoal, viral, opportunistic, and reactivation of latent infections)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal pain, acute myelocytic leukemia, alopecia, anemia, arthralgia, bone marrow depression, hemorrhage, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatosplenic T-cell lymphomas, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hypersensitivity, hypotension, interstitial pneumonitis (reversible), JC virus infection, macrocytic anemia, malignant lymphoma, malignant neoplasm of skin, negative nitrogen balance, pancreatitis, pancytopenia, progressive multifocal leukoencephalopathy, skin rash, steatorrhea, Sweet's syndrome (acute febrile neutrophilic dermatosis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138202\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to azathioprine or any component of the formulation; pregnancy (in patients with rheumatoid arthritis [see Pregnancy Considerations]); patients with rheumatoid arthritis and a history of treatment with alkylating agents (eg, cyclophosphamide, chlorambucil, melphalan) may have a prohibitive risk of malignancy with azathioprine treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138184\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: The frequency of gastrointestinal adverse effects (nausea and vomiting) may be decreased with dividing dose or administering after meals. Gastrointestinal hypersensitivity with severe nausea and vomiting has been reported; diarrhea, rash, fever, malaise, myalgia, hypotension, and liver enzyme abnormalities may also occur. Symptoms usually develop within the first several weeks of treatment and are generally reversible upon discontinuation; may recur upon rechallenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicity: Dose-related hematologic toxicities (leukopenia, thrombocytopenia, and anemias, including macrocytic anemia and/or pancytopenia) may occur; may be severe and/or delayed. Thiopurine methyltransferase (TPMT) genotyping or phenotyping may help to identify patients who are at an increased risk for developing azathioprine toxicity. Patients with intermediate TPMT activity may be at increased risk for hematologic toxicity at conventional azathioprine doses; patients with low or absent TPMT activity are at risk for severe, life-threatening myelotoxicity. Myelosuppression may be more severe with renal transplants undergoing rejection. Monitor CBC with differential and platelets weekly during the first month, then twice a month for 2 months, then monthly (or more frequently if clinically indicated). May require treatment interruption or dose reduction. Leukopenia does not correlate with therapeutic effect and the dose should not be increased intentionally to lower the white blood cell count.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity (transaminase, bilirubin, and/or alkaline phosphatase elevations) may occur, usually in renal transplant patients. Usually occurs within 6 months of transplant and is normally reversible with discontinuation. Monitor liver function periodically. Rarely, hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]) has been reported; discontinue if hepatic SOS is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Chronic immunosuppression increases the risk of serious, sometimes fatal, infections (bacterial, viral, fungal, protozoal, and opportunistic), including reactivation of latent infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Chronic immunosuppression with azathioprine (a purine antimetabolite), increases the risk of malignancy. Malignancies reported have included post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Health care providers using this medication should be very familiar with this risk, as well as with the mutagenic potential to both men and women, and with possible hematologic toxicities. Patients should be informed of the risk for malignancy development.</b> HSTCL is a rare white blood cell cancer that is usually fatal and has predominantly occurred in adolescents and young adults treated for Crohn disease or ulcerative colitis and receiving TNF blockers (eg, adalimumab, certolizumab pegol, etanercept, golimumab), azathioprine, and/or mercaptopurine. Most cases of HSTCL have occurred in patients treated with a combination of immunosuppressant agents, although there have been reports of HSTCL in patients receiving azathioprine or mercaptopurine monotherapy. Renal transplant patients are known to be at increased risk for malignancy (eg, skin cancer, lymphoma), the risk is increased with aggressive immunosuppression. Limit sun and ultraviolet light exposure and use appropriate sun protection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy: Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including azathioprine (some cases have been fatal). Risk factors for PML include treatment with immunosuppressants and immune system impairment. Consider a diagnosis of PML in any patient presenting with new-onset neurological manifestations; consultation with a neurologist as clinically indicated may be warranted. Consider decreasing the degree of immunosuppression with respect to the risk of organ rejection in transplant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; TPMT deficiency: Patients with genetic deficiency of TPMT are more sensitive to myelosuppressive effects. Patients with intermediate TPMT activity may be at risk for increased myelosuppression; those with low or absent TPMT activity are at risk for developing severe and life-threatening hematologic toxicity. TPMT genotyping or phenotyping may assist in identifying patients at risk for developing toxicity. Consider TPMT testing in patients with abnormally low CBC unresponsive to dose reduction. TPMT testing does not substitute for CBC monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mercaptopurine: Azathioprine is metabolized to mercaptopurine; concomitant use may result in profound myelosuppression and should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; TPMT or xanthine oxidase inhibitors: Patients on concurrent therapy with drugs which may inhibit TPMT (eg, olsalazine) or xanthine oxidase (eg, allopurinol) may be sensitive to myelosuppressive effects. Dose adjustment of azathioprine may be recommended when used concurrently with allopurinol; patients with low or absent TPMT activity may require further dose reductions or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Immune response to vaccines may be diminished.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced health care provider: <b>[US Boxed Warning]: Should be prescribed by health care providers familiar with the risks, including hematologic toxicities and mutagenic potential. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819861\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The development of secondary hemophagocytic lymphohistiocytosis (HLH), a rare and frequently fatal activation of macrophages which causes phagocytosis of all bone marrow blood cell lines, is increased (100-fold) in pediatric patients diagnosed with inflammatory bowel disease due to chronic inflammation; this risk is further increased with concomitant thiopurine (ie, azathioprine or mercaptopurine) therapy, Epstein-Barr virus, or possibly other infections; if patient on thiopurine therapy presents with fever for at least 5 days, cervical lymphadenopathy, and lymphopenia, discontinue immunosuppressive therapy and further diagnostic evaluation for HLH should be performed; delay in diagnosis has been associated with increased mortality (Biank, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298801\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138189\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12923&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May decrease the metabolism of Thiopurine Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May increase serum concentrations of the active metabolite(s) of AzaTHIOprine. More specifically, allopurinol may increase mercaptopurine serum concentrations and promote formation of active thioguanine nucleotides. Management: Reduce the azathioprine dose to one third to one quarter of the usual dose if used concomitantly with allopurinol, and monitor closely for systemic toxicity (particularly hematologic toxicity, nausea, and vomiting).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the myelosuppressive effect of AzaTHIOprine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased.<b> Exceptions: </b>Lenalidomide; Pomalidomide; Thalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: AzaTHIOprine may enhance the hepatotoxic effect of Cyclophosphamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Febuxostat: May increase the serum concentration of AzaTHIOprine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">InFLIXimab: May enhance the adverse/toxic effect of AzaTHIOprine. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. InFLIXimab may increase serum concentrations of the active metabolite(s) of AzaTHIOprine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: AzaTHIOprine may enhance the myelosuppressive effect of Mercaptopurine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): May increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased. Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients extra closely for signs/symptoms of myelosuppression.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): May increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased. Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients closely for signs/symptoms of myelosuppression.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfamethoxazole: May enhance the myelosuppressive effect of AzaTHIOprine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the myelosuppressive effect of AzaTHIOprine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): AzaTHIOprine may enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live).  Management: Low-dose azathioprine (3 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of azathioprine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): AzaTHIOprine may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138191\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1620142\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Azathioprine crosses the placenta in humans; congenital anomalies, immunosuppression, hematologic toxicities (lymphopenia, pancytopenia), and intrauterine growth retardation have been reported. Women of childbearing potential should avoid becoming pregnant during treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intrauterine growth retardation and preterm delivery are also reported in pregnancies following a kidney transplant. Stable immunosuppression is required in pregnant women who have had a kidney transplant and an increased risk of fetal malformations has not been observed with azathioprine; doses &le;2 mg/kg/day are recommended (Durst 2015; Hou 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Although contraindicated by the manufacturer, available guidelines suggest that use of azathioprine is acceptable for the treatment of rheumatoid arthritis (Flint 2016). Azathioprine may also be used for the adjunctive treatment of lupus nephritis in pregnant women (Hahn 2012). Both guidelines recommend doses &le;2 mg/kg/day during pregnancy (Flint 2016; Hahn 2012). Agents other than azathioprine are recommended for the treatment of immune thrombocytopenia (Neunert 2011) and inflammatory bowel disease (van der Woude 2015) in pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045372\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (weekly during first month, twice monthly for months 2 and 3, then monthly; monitor more frequently with dosage modifications), total bilirubin, liver function tests, creatinine clearance, TPMT genotyping or phenotyping (consider TPMT testing in patients with abnormally low CBC unresponsive to dose reduction); monitor for symptoms of infection</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For use as immunomodulatory therapy in inflammatory bowel disease (Crohn disease or ulcerative colitis), monitor CBC with differential weekly for 1 month, then biweekly for 1 month, followed by monitoring every 1-2 months throughout the course of therapy; monitor more frequently if symptomatic. LFTs should be assessed every 3 months. Monitor for signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138183\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Azathioprine is an imidazolyl derivative of mercaptopurine; metabolites are incorporated into replicating DNA and halt replication; also block the pathway for purine synthesis (Taylor 2005). The 6-thioguanine nucleotide metabolites appear to mediate the majority of azathioprine&rsquo;s immunosuppressive and toxic effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138201\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immune thrombocytopenia (oral): Initial response: 30 to 90 days; Peak response: 30 to 120 days (Neunert 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; metabolized to 6-mercaptopurine via glutathione S-transferase (GST) reduction. Further metabolized (in the liver and GI tract) via three major pathways: Hypoxanthine guanine phosphoribosyltransferase (to active metabolites: 6-thioguanine-nucleotides, or 6-TGNs), xanthine oxidase (to inactive metabolite: 6-thiouric acid), and thiopurine methyltransferase (TPMT) (to inactive metabolite: 6-methylmercaptopurine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Azathioprine and mercaptopurine: Variable: ~2 hours (Taylor 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Oral: 1 to 2 hours (including metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138200\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">A 50 mg/mL oral suspension may be prepared with tablets. Crush one-hundred-twenty 50 mg tablets in a mortar and reduce to a fine powder. Add 40 mL of either cherry syrup (diluted 1:4 with Simple Syrup, USP); a 1:1 mixture of Ora-Sweet and Ora-Plus; or a 1:1 mixture of Ora-Sweet SF and Ora-Plus, and mix to a uniform paste. Mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &quot;shake well&quot;, &quot;refrigerate&quot;, and &quot;protect from light&quot;. Stable for 60 days refrigerated.</p>\n    <div class=\"reference\">Allen LV Jr and Erickson MA 3rd, &quot;Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids,&quot; <i>Am J Health Syst Pharm</i>, 1996, 53(16):1944-9.<span class=\"pubmed-id\">8862208</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138204\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (AzaTHIOprine Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $300.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Azasan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $1,898.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $846.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (AzaTHIOprine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $211.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Imuran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $803.10</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138206\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aza-Q (DE);</li>\n      <li>Azadus (TH);</li>\n      <li>Azafalk (DE);</li>\n      <li>Azafrine (KR);</li>\n      <li>Azamun (AE, AU, MY, NZ, SA, TW);</li>\n      <li>Azamune (GB);</li>\n      <li>Azanin (JP);</li>\n      <li>Azapin (AU);</li>\n      <li>Azapress (ZA, ZW);</li>\n      <li>Azaprin (AE, KW, QA, SA);</li>\n      <li>Azaprine (KR);</li>\n      <li>Azarekhexal (EE);</li>\n      <li>Azarex (DE);</li>\n      <li>Azathiodura (DE);</li>\n      <li>Azatioprina (PE);</li>\n      <li>Azatioprina Wellcome (IT);</li>\n      <li>Azatrilem (MX);</li>\n      <li>Azopi (IL);</li>\n      <li>Azoran (IN);</li>\n      <li>Azostal (LK);</li>\n      <li>Colinsan (DE);</li>\n      <li>Immuthera (KR);</li>\n      <li>Imuger (IE);</li>\n      <li>Imunen (BR);</li>\n      <li>Imuprin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, FI, GH, GM, GN, GY, HK, IQ, IR, JM, JO, KE, KW, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, OM, PR, SA, SC, SD, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, YE, ZM, ZW);</li>\n      <li>Imuprine (NZ);</li>\n      <li>Imuran (AE, AR, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CI, CL, CN, CO, CY, CZ, EC, EE, EG, ET, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, JM, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NZ, OM, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SG, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VN, YE, ZM, ZW);</li>\n      <li>Imurek (AT, CH, DE);</li>\n      <li>Imurel (DK, ES, FI, FR, IS, NO, SE, VN);</li>\n      <li>Renzat (PH);</li>\n      <li>Thioprine (AU);</li>\n      <li>Transimune (IN);</li>\n      <li>Zaprine (ZA);</li>\n      <li>Zytrim (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adams A, MacDermott EJ, and Lehman TJ, &quot;Pharmacotherapy of Lupus Nephritis in Children: A Recommended Treatment Approach,&quot; <i>Drugs</i>, 2006, 66(9):1191-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/16827597/pubmed\" target=\"_blank\" id=\"16827597\">16827597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians, 2007, p. 97, 177.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ashraf VV, Taly AB, Veerendrakumar M, et al, &quot;Myasthenia Gravis in Children: A Longitudinal Study,&quot; <i>Acta Neurol Scand</i>, 2006, 114(2):119-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/16867035/pubmed\" target=\"_blank\" id=\"16867035\">16867035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertsias GK, Tektonidou M, Amoura Z, et al, &quot;Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) Recommendations for the Management of Adult and Paediatric Lupus Nephritis,&quot; <i>Ann Rheum Dis</i>, 2012, 71(11):1771-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/22851469/pubmed\" target=\"_blank\" id=\"22851469\">22851469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biank VF, Sheth MK, Talano J, et al, &quot;Association of Crohn's Disease, Thiopurines, and Primary Epstein-Barr Virus Infection With Hemophagocytic Lymphohistiocytosis,&quot;<i> J Pediatr</i>, 2011, 159(5):808-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/21722918/pubmed\" target=\"_blank\" id=\"21722918\">21722918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boruchov DM, Gururangan S, Driscoll MC, et al, &quot;Multiagent Induction and Maintenance Therapy for Patients With Refractory Immune Thrombocytopenic Purpura (ITP),&quot; <i>Blood</i>, 2007, 110(10):3526-31. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/17698634/pubmed\" target=\"_blank\" id=\"17698634\">17698634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Della Corte C, Sartorelli MR, Sindoni CD, et al, &quot;Autoimmune Hepatitis in Children: An Overview of the Disease Focusing on Current Therapies,&quot; <i>Eur J Gastroenterol Hepatol</i>, 2012, 24(7):739-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/22495399/pubmed\" target=\"_blank\" id=\"22495399\">22495399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denfield SW, &quot;Strategies to Prevent Cellular Rejection in Pediatric Heart Transplant Recipients,&quot; <i>Paediatr Drugs</i>, 2010, 12(6):391-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/21028918/pubmed\" target=\"_blank\" id=\"21028918\">21028918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ford KA, &quot;Paediatric Immunosuppression Following Solid Organ Transplantation,&quot; <i>Arch Dis Child Educ Pract</i>, 2006, 91:ep87-ep91.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuentes D, Torrente F, Keady S, et al, &quot;High-Dose Azathioprine in Children With Inflammatory Bowel Disease,&quot;<i> Aliment Pharmacol Ther</i>, 2003, 17(7):913-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/12656694/pubmed\" target=\"_blank\" id=\"12656694\">12656694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goebel JC, Roesel M, Heinz C, et al, &quot;Azathioprine as a Treatment Option for Uveitis in Patients With Juvenile Idiopathic Arthritis,&quot; <i>Br J Ophthalmol</i>, 2011, 95(2):209-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/20584711/pubmed\" target=\"_blank\" id=\"20584711\">20584711</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grossman AB, Noble AJ, Mamula P, et al, &quot;Increased Dosing Requirements for 6-Mercaptopurine and Azathioprine in Inflammatory Bowel Disease Patients Six Years and Younger,&quot; <i>Inflamm Bowel Dis</i>, 2008, 14(6):750-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/18266236/pubmed\" target=\"_blank\" id=\"18266236\">18266236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hashkes PJ and Laxer RM, &quot;Medical Treatment of Juvenile Idiopathic Arthritis,&quot; <i>JAMA</i>, 2005, 294(13):1671-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/16204667/pubmed\" target=\"_blank\" id=\"16204667\">16204667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imuran (azathioprine) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc: February 2014. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kemper AR, Coeytaux R, Sanders GD, et al, &quot;Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA),&quot; Agency for Healthcare Research and Quality, AHRQ Comparative Effectiveness Reviews, 2011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/22091470/pubmed\" target=\"_blank\" id=\"22091470\">22091470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kvien TK, Hoyeraal HM, and Sandstad B, &quot;Azathioprine Versus Placebo in Patients With Juvenile Rheumatoid Arthritis: A Single Center Double Blind Comparative Study,&quot; <i>J Rheumatol</i>, 1986, 13(1):118-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/3517321/pubmed\" target=\"_blank\" id=\"3517321\">3517321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leichter HE, Sheth KJ, Gerlach MJ, et al, &ldquo;Outcome of Renal Transplantation in Children Aged 1-5 and 6-18 Years,&rdquo; <i>Child Nephrol Urol</i>, 1992, 12(1):1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/1606573/pubmed\" target=\"_blank\" id=\"1606573\">1606573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindner A, Schalke B, and Toyka KV, &quot;Outcome in Juvenile-Onset Myasthenia Gravis: A Retrospective Study With Long-Term Follow-Up of 79 Patients,&quot; <i>J Neurol</i>, 1997, 244(8):515-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/9309559/pubmed\" target=\"_blank\" id=\"9309559\">9309559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marks SD and Tullus K, &quot;Modern Therapeutic Strategies for Paediatric Systemic Lupus Erythematosus and Lupus Nephritis,&quot; <i>Acta Paediatr</i>, 2010, 99(7):967-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/20222881/pubmed\" target=\"_blank\" id=\"20222881\">20222881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palace J, Newsom-Davis J, and Lecky B, &quot;A Randomized Double-Blind Trial of Prednisolone Alone or With Azathioprine in Myasthenia Gravis. Myasthenia Gravis Study Group,&quot; <i>Neurology</i>, 1998, 50(6):1778-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/9633727/pubmed\" target=\"_blank\" id=\"9633727\">9633727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Punati J, Markowitz J, Lerer T, et al, &quot;Effect of Early Immunomodulator Use in Moderate to Severe Pediatric Crohn Disease,&quot; <i>Inflamm Bowel Dis</i>, 2008, 14(7):949-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/18306311/pubmed\" target=\"_blank\" id=\"18306311\">18306311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riello L, Talbotec C, Garnier-Lenglin&eacute; H, et al, &quot;Tolerance and Efficacy of Azathioprine in Pediatric Crohn's Disease,&quot;<i> Inflamm Bowel Dis</i>, 2011, 17(10):2138-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/21910176/pubmed\" target=\"_blank\" id=\"21910176\">21910176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandhu BK, Fell JME, Beattie RM, et al, &quot;Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom,&quot; <i>JPGN</i>, 2010, 50:S1-S13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sathasivam S, &quot;Steroids and Immunosuppressant Drugs in myasthenia Gravis,&quot; <i>Nat Clin Pract Neurol</i>, 2008, 4(6):317-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/18493241/pubmed\" target=\"_blank\" id=\"18493241\">18493241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. <i>Crit Rev Oncol Hematol</i>. 2005;56(1):23-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/16039869/pubmed\" target=\"_blank\" id=\"16039869\">16039869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vitfell-Pedersen J, Jorgensen MH, M&uuml;ller K, et al, &quot;Autoimmune Hepatitis in Children in Eastern Denmark,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2012, 55(4):376-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-pediatric-drug-information/abstract-text/22644464/pubmed\" target=\"_blank\" id=\"22644464\">22644464</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12923 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708623\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F138216\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F138217\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045373\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045366\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F138195\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F138180\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045376\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130888\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F138211\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045375\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F138271\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F138268\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F138202\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F138184\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819861\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298801\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F138189\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F138191\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1620142\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045372\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F138183\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F138201\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F138200\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F138204\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F138206\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12923|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">Azathioprine: Drug information</a></li><li><a href=\"topic.htm?path=azathioprine-patient-drug-information\" class=\"drug drug_patient\">Azathioprine: Patient drug information</a></li></ul></div></div>","javascript":null}